Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blind, Placebo- and Active-control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee.

NCT00486811 is registered in ClinicalTrials.gov with Grünenthal GmbH as lead sponsor.

NCT NCT00486811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00486811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blind, Placebo- and Active-control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee.
Lead sponsor
Grünenthal GmbH
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2007
Completion date
July 31, 2008
Enrollment
990 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

knee osteoarthritis, pain